Ocular Therapeutix (NASDAQ:OCUL) Director Acquires $461,354.14 in Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Director Richard Md Lindstrom bought 60,229 shares of the company’s stock in a transaction on Friday, February 20th. The stock was bought at an average price of $7.66 per share, for a total transaction of $461,354.14. Following the completion of the purchase, the director owned 246,933 shares of the company’s stock, valued at approximately $1,891,506.78. The trade was a 32.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Ocular Therapeutix Trading Up 0.9%

Shares of Ocular Therapeutix stock opened at $9.59 on Friday. The stock has a market capitalization of $2.09 billion, a P/E ratio of -6.66 and a beta of 0.90. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.32 and a current ratio of 15.39. The stock’s 50-day simple moving average is $10.38 and its 200 day simple moving average is $11.59.

Ocular Therapeutix (NASDAQ:OCUL) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. The firm had revenue of $13.25 million for the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business’s quarterly revenue was down 22.4% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.29) earnings per share. As a group, research analysts anticipate that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Institutional Trading of Ocular Therapeutix

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Seven Fleet Capital Management LP bought a new stake in shares of Ocular Therapeutix in the fourth quarter worth about $208,000. Virtu Financial LLC boosted its stake in shares of Ocular Therapeutix by 470.2% during the 4th quarter. Virtu Financial LLC now owns 65,627 shares of the biopharmaceutical company’s stock worth $797,000 after purchasing an additional 54,117 shares during the period. XTX Topco Ltd boosted its position in shares of Ocular Therapeutix by 42.5% during the fourth quarter. XTX Topco Ltd now owns 49,073 shares of the biopharmaceutical company’s stock valued at $596,000 after buying an additional 14,640 shares during the period. Voloridge Investment Management LLC bought a new stake in shares of Ocular Therapeutix during the 4th quarter worth approximately $9,859,000. Finally, Wellington Management Group LLP lifted its position in shares of Ocular Therapeutix by 20.7% during the fourth quarter. Wellington Management Group LLP now owns 74,317 shares of the biopharmaceutical company’s stock worth $902,000 after purchasing an additional 12,753 shares during the last quarter. Institutional investors own 59.21% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OCUL. Wall Street Zen upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Saturday, February 7th. TD Cowen reiterated a “buy” rating on shares of Ocular Therapeutix in a research report on Thursday, October 30th. HC Wainwright raised their price target on Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Royal Bank Of Canada reissued an “outperform” rating and issued a $30.00 target price on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Ocular Therapeutix in a research report on Tuesday, February 17th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard Lindstrom bought 60,229 shares at ~ $7.66, increasing his stake ~32% — a notable insider purchase that signals confidence and provides direct demand support. SEC Filing – Lindstrom Form 4
• Positive Sentiment: Ocular will present detailed SOL‑1 data at the Macula Society meeting and host investor events — favorable readouts or constructive management commentary could be a major catalyst for the stock and offset recent weakness. SOL‑1 Presentation
• Positive Sentiment: Large institutional holders have been adding to positions (Vanguard, Avoro, TCG Crossover, Adage, Geode), which supports longer‑term demand even amid short‑term volatility. MarketBeat Institutional Summary
• Neutral Sentiment: Analyst coverage remains mixed-to-positive overall (consensus “Moderate Buy,” average target ~$23.78) — this keeps a bullish case intact but creates a wide range of expectations that earnings or SOL‑1 commentary could swing stock directionally. MarketBeat Summary
• Neutral Sentiment: Smaller, individual insider sales (e.g., Nadia Waheed sold 3,510 shares at ~$7.74) appear modest relative to major holdings and are unlikely alone to change long‑term conviction. SEC Filing – Waheed Form 4
• Negative Sentiment: Several executives/directors sold shares on Feb. 23 (Sanjay Nayak, Jeffrey Heier, Peter Kaiser and Pravin Dugel — Dugel sold 20,056 shares) at roughly $8.28; clustered insider selling increases available float and weighs on near‑term sentiment. SEC Filing – Dugel Form 4
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (~6.9% of the float), elevating bearish pressure and the potential for sharper downside or volatile moves ahead of catalysts. (Days‑to‑cover ~3.0.)
• Negative Sentiment: Needham trimmed its price target to $18 (from $20), a downgrade that could temper enthusiasm among some growth/biotech investors despite other higher targets. Needham Price Target Cut

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.